# 510(k) SUMMARY

This summary of $5 1 0 ( \mathbf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is K111753.

807.92 (a)(1): Name: Hitachi Chemical Diagnostics Address: 630 Clyde Court Mountain View, CA 94043

Phone: (650) 961 5501 FAX: (650) 969 2745 Contact: Mr. Bunichiro Nakajima

807.92 (a)(2): Device name- trade name and common name, and classification

# Trade name:

Hitachi Clinical Analyzer S TEST Reagent Cartridge Cholesterol (CHO)   
Hitachi Clinical Analyzer S TEST Reagent Cartridge High Density Lipoprotein Cholesterol (HDL) . ... L   
Hitachi Clinical Analyzer S TEST Reagent Cartridge Low Density Lipoprotein Cholesterol (LDL)   
Hitachi Clinical Analyzer S TEST Reagent Cartridge Triglycerides (TG)

Common Name: Routine chemistry analyzer for lipid panel: total cholesterol (CHO), HDL, LDL, and triglycerides (TG)

Classifications: 21 CFR $\ S$ 862.1175- Cholesterol (total) test system 21 CFR $\ S$ 862.1475- Lipoprotein (HDL, LDL) test system 21 CFR $\ S$ 862.1705- Triglyceride test system All Class I Reserved, per 21 CFR 862.9(c)(4)

807.92 (a)(3): Identification of the legally marketed predicate devices

Instrument portion: Roche/Hitachi cobas 6000- K060373   
Total cholesterol: Roche/Hitachi test reagent- K031824   
HDL: Roche/Hitachi test reagent- K033610   
LDL: Roche/Hitachi test reagent- K012287

# TG: Roche/Hitachi test reagent- K972250

Integrated system (instrument and lipid panel): Alfa Wasserman S40 systemK091413

# 807.92 (a)(4): Device Description

The Hitachi Clinical Analyzer is an automatic, bench-top, wet chemistry system intended for use in clinical laboratories or physician office laboratories. The instrument consists of a desktop analyzer unit, an operations screen that prompts the user for operation input and displays data, a printer, and a unit cover. The analyzer unit includes a single probe, an incubation rotor, carousels for sample cups and reagent cartridges, and a multi-wavelength photometer. The single-use reagent cartridges may be placed in any configuration on the carousel, allowing the user to develop any test panel where the reagent cartridges are available.

The S TEST reagent cartridges are made of plastic and include two small reservoirs capable of holding two separate reagents (R1 and R2), separated by a reaction cell/photometric cuvette. The cartridges also include a dot code label that contains all chemistry parameters, calibration factors, and other production-related information, e.g., expiration dating. The dimensions of the reagent cartridges are: $1 3 . 5 \ \mathrm { m m } ( \mathrm { W } ) \times 2 8 \ \mathrm { m m } ( \mathrm { D } ) \times 2 0 . 2 \ \mathrm { m m } ($ H).

System operation: After the sample cup is placed into the carousel, the analyzer pipettes the sample, pipettes the reagent, and mixes (stirs) the sample and reagent together. After the sample and reagent react in the incubator bath, the analyzer measures the absorbance of the sample, and based on the absorbance of the reactions, it calculates the concentration of analyte in the sample. The test system can measure analytes in serum or heparin plasma and results are available in approximately 15 minutes per test. This submission is for the Lipid Panel, consisting of reagent cartridges for total cholesterol, HDL, LDL, and triglycerides.

# Chemistry reactions:

# Cholesterol

The cholesterol in the sample is cleaved into cholesterol esters and free cholesterol. The cholesterol esters become free' cholesterol through the action of cholesterol esterase (CE). The free cholesterol is then oxidized by cholesterol oxidase (COD) to produce hydrogen peroxide, esters and free cholesterol. The cholesterol esters become free cholesterol through the action of cholesterol esterase (CE). The hydrogen peroxide oxidizes and condenses 4- aminoaminoantipyrine and N-ethyl-N-sulfobutyl-m-toluidine (ESBmT) under the influence of peroxidase (POD) to 'produce'a"reddish-purple pigment. 'Total'cholesterol concentration is determined by measuring the absorbance of this reddish-purple pigment. The difference in absorbance, monitored bichromatically at $6 0 0 ~ \mathrm { { \ n m } / 8 0 0 ~ \mathrm { { n m } } }$ , is directly proportional to the cholesterol concentration in the sample:

By using a special surface-active agent that preferentially solubilizes HDL and not other lipoproteins (LDL, VLDL, and chylomicrons), the HDL cholesterol is measured via a quickly initiated enzymatic reaction. Therefore, only HDL cholesterol is specifically measured. The released hydrogen peroxide oxidizes and condenses 4-aminoaminoantipyrine and N,N'-bis(4- sulfobutyl)-m-toluidine disodium salt (DSBmT) in the presence of peroxidase (POD) to produce a reddish-purple pigment. HDL cholesterol concentration is determined by measuring the absorbance of this reddish-purple pigment. The difference in absorbance, monitored bichromatically at $6 0 0 \ \mathrm { n m } / 7 0 0 \ \mathrm { n m }$ is directly proportional to the HDL concentration in the sample.

# LDL

The method, using a combination of two surfactants, is based on the principle that each lipoprotein reacts with different surfactants, depending on their intrinsic physicochemical property. In the first reaction, Surfactant 1 changes the structure of only those lipoproteins other than LDL (i.e., chylomicron [CM], VLDL, and HDL), and the resulting micellar cholesterol is consumed by the cholesterol oxidase and the cholesterol esterase in a colorless reaction. In the second reaction, the remaining LDL is modified by Surfactant 2, and that form of cholesterol is measured in a color reaction.

# TG

Free glycerol in the sample is converted to glycerol-3-phosphoric acid through the action of glycerol kinase (GK) and the adenosine triphosphate (ATP) substrate. Glycerol-3-phosphoric acid is converted to hydrogen peroxide via the action of glycerol-3-phosphate oxidase (GPO); peroxide is then decomposed into water and oxygen via the action of catalase. The neutral fat in the sample is quickly hydrolyzed into glycerol and fatty acid by the lipoprotein lipase (LPL) contained in the second reagent. The glycerol product is converted to glycerol-3-phosphoric acid via the action of GK and the ATP substrate, which in turn produces hydrogen peroxide via the action of GPO. The hydrogen peroxide oxidizes/condenses 4-aminoantipyrine and N-ethyl-Nsulfobutyl-m-toluidine (ESBmT), via the action of peroxidase (POD) to produce a reddish purple pigment. The original neutral fat concentration (triglyceride) is determined by measuring the absorbance of the reddish purple pigment produced. The difference in absorbance between the final reading and the blank," monitored bichromatically at $6 0 0 \ \mathrm { \ n m } / 8 0 0 \ \mathrm { \ n m }$ , is directly proportional to the triglyceride concentration.

# 807.92 (a)(5): Intended Use

The Hitachi Clinical Analyzer with S TEST reagent cartridges for total cholesterol (CHO), HDL cholesterol' (HDL), LDL cholesterol (LDL), and triglycerides (TG) is intended for the quantitative measurements of CHO, HDL, LDL, and TG in serum or heparinized plasma. The test system is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only. I . '

Cholesterol measurements are used in the diagiosis and treatment of disorders involving excess cholesterol in the blood, and lipid and lipoprotein metabolism disorders.

Page 3 of 14

![](images/a49977675b457b28582d93b1769e3aebbfa6b93f3c08cca55d1f244e1b8d1244.jpg)

HDL measurements (lipoproteins) are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. . LDL measurements (lipoproteins) are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.

# 807.92 (a)(6): Technological Similarities and Differences to the Predicate

The following chart describes similarities and differences between the two test systems.

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Hitachi S TEST Systems</td><td rowspan=1 colspan=1>PREDICATE(S)</td></tr><tr><td rowspan=1 colspan=1>Instrument Platform</td><td rowspan=1 colspan=1>Hitachi Clinical Analyzer</td><td rowspan=1 colspan=1>Roche cobas 6000 - K060373</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>also, AIfa Wasserman S40- K091413</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>K number- K111753</td><td rowspan=1 colspan=1>Roche K number- K031824</td></tr><tr><td rowspan=1 colspan=1>Device Class, Regulation Code</td><td rowspan=1 colspan=1>Class I (reserved), 21 CFR 862.1175</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Classification Product Code</td><td rowspan=1 colspan=1>CHH</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative determination of totalcholesterol</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Testing Environment</td><td rowspan=1 colspan=1>Physician office (POL) or clinical lab</td><td rowspan=1 colspan=1>Clinical lab- cobas POL/Clin Lab - Alfa Wasserman</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>1.            method)</td><td rowspan=1 colspan=1>Enzymatic (cholesterol esterase andcholesterol oxidase)</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum and heparinized plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>4 to 400 mg/dL</td><td rowspan=1 colspan=1>3.86 to 800 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>600/800 nmS:</td><td rowspan=1 colspan=1>. 700/505 nm</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>0.7 mg/dL</td><td rowspan=1 colspan=1>3.86 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>1 to 435 mg/dL</td><td rowspan=1 colspan=1>3.86 to 800 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CVs range from 0.5% to 1.4%(POL testing)</td><td rowspan=1 colspan=1>%CVs range from 1.4% to 1.6%(from product labeling)</td></tr><tr><td rowspan=1 colspan=1>.</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HDL</td><td rowspan=1 colspan=1>K number- K111753</td><td rowspan=1 colspan=1>Roche K number- K033610</td></tr><tr><td rowspan=1 colspan=1>Device Class, Regulation Code</td><td rowspan=1 colspan=1>Class I (reserved), 21 CFR 862.1475</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Classification Product Code</td><td rowspan=1 colspan=1>.             LBS               *</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative determination of HDLcholesterol</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Testing Environment</td><td rowspan=1 colspan=1>Physician office or clinical lab</td><td rowspan=1 colspan=1>Clinical lab- cobasPOL/Clin Lab - Alfa Wasserman</td></tr></table>

Page 4 of 14

$\circledast$ Hitachl Chemical Diagnostics, Inc. 630 Clyde Court, Mountain Vlew, CA 94043-2239 Tel: 800 233 6270 Fax: 650 969 2745

<table><tr><td></td><td>www.hcdiagnostics.com 1 1 0</td><td></td></tr></table>

Comparative chart- continued   

<table><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Enzymatic direct method</td><td rowspan=1 colspan=1>Enzymatic (cholesterol esterase andcholesterol oxidase) after removal ofLDL and VLDL</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum and heparinized plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>8 mg/dL to 150 mg/dL</td><td rowspan=1 colspan=1>3 to 121 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>600/700 nm</td><td rowspan=1 colspan=1>700/600 nm</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>0.6 mg/dL</td><td rowspan=1 colspan=1>3 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>4 mg/dL to 485 mg/dL</td><td rowspan=1 colspan=1>3 to 121 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CVs range from 1.0% to 4.5%(from POL testing)</td><td rowspan=1 colspan=1>%CVs range from 0.9% to 1.5%(from product labeling)</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>Hitachi S TEST Systems</td><td rowspan=1 colspan=1>PREDICATE(S)</td></tr><tr><td rowspan=1 colspan=1>LDL</td><td rowspan=1 colspan=1>K number- K111753</td><td rowspan=1 colspan=1>Roche K number- K033610</td></tr><tr><td rowspan=1 colspan=1>Device Class, Regulation Code</td><td rowspan=1 colspan=1>Class I (reserved), 21 CFR 862.1475</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Classification Product Code</td><td rowspan=1 colspan=1>MRR</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative determination of LDLcholesterol</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Testing Environment</td><td rowspan=1 colspan=1>Physician office or clinical lab•</td><td rowspan=1 colspan=1>Clinical lab- cobasPOL/Clin Lab - Alfa Wasserman</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Enzymatic direct method</td><td rowspan=1 colspan=1>Homogeneous enzymaticcolorimetric</td></tr><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum and heparinized plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>8 to 400 mg/dL</td><td rowspan=1 colspan=1>3.86 to 548 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>546/660 nm</td><td rowspan=1 colspan=1>700/600 nm</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>. 0.8 mg/dL</td><td rowspan=1 colspan=1>3.86 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>3 to 430 mg/dL</td><td rowspan=1 colspan=1>3.86 to 548 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CVs range from 1.3% to 2.0%(from POL testing)</td><td rowspan=1 colspan=1>%CVs range from 1.9% to 2.7%(from product labeling)</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>cYanmaGenntaellowb</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>K number- K111753</td><td rowspan=1 colspan=1>Roche K number- K972250</td></tr><tr><td rowspan=1 colspan=1>Device Class, Regulation Code</td><td rowspan=1 colspan=1>Class I (reserved), 21 CFR 862.1705</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Classification Product Code</td><td rowspan=1 colspan=1>CDT  4  in</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Quantitative determination of;,,     triglycerides</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Testing Environment</td><td rowspan=1 colspan=1>Physician office or clinical lab</td><td rowspan=1 colspan=1>Clinical lab- cobasPOL/Clin Lab - Alfa Wasserman</td></tr><tr><td rowspan=1 colspan=1>Test Principle</td><td rowspan=1 colspan=1>Enzymatic method</td><td rowspan=1 colspan=1>Enzymatic and colorimetric</td></tr></table>

Page 5 of 14

HitachiChemical Dlagnostlcs,Inc 630 Clyde Couri, Mountain Vlew, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745

<table><tr><td></td><td>&#x27; i : : e 1</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Specimen Type</td><td rowspan=1 colspan=1>Serum and heparinized plasma</td><td rowspan=1 colspan=1>Same (plus EDTA plasma)</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>7 mg/dL to 800 mg/dL</td><td rowspan=1 colspan=1>8.85 to 885 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Detection Wavelength</td><td rowspan=1 colspan=1>570/700 nm</td><td rowspan=1 colspan=1>700/505 nm</td></tr><tr><td rowspan=1 colspan=1>Detection Limit</td><td rowspan=1 colspan=1>2.5 mg/dL</td><td rowspan=1 colspan=1>8.85 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>2 to 848 mg/dL</td><td rowspan=1 colspan=1>8.85 to 885 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Precision</td><td rowspan=1 colspan=1>%CVs range from 1.1% to 4.1%(from POL testing)</td><td rowspan=1 colspan=1>%CVs range from 1.6% to 2.0%(from product labeling)</td></tr></table>

# 807.92 (b)(1): Brief Description of Nonclinical Data

A series of studies were performed that evaluated the following nonclinical performance characteristics for each analyte: analytical sensitivity (limits of detection), linearity, 20-day inhouse precision, interference testing, in-house method comparisons, and matrices comparison between serum and heparin plasma.

Analytical Sensitivity (Limits of Detection)

The studies followed CLSI EP17-A for each analyte. The sensitivities were as follows:

CHO: $0 . 7 \mathrm { m g / d L }$ HDL: $0 . 6 \mathrm { m g / d L }$ LDL: $0 . 8 ~ \mathrm { m g / d L }$ TG: EPY $2 . 5 ~ \mathrm { m g / d L }$

Linearity The studies followed CLSI EP-6A for each analyte. The ranges of linearity were as follows:

CHO: $1 ~ \mathrm { m g / d L }$ to $4 3 5 \mathrm { m g / d L }$ HDL: $4 \mathrm { m g / d L }$ to $4 8 5 \mathrm { m g / d L }$ EY LDL: $3 ~ \mathrm { m g / d L }$ to $4 3 0 \mathrm { m g / d L }$ TG: $2 \ : \mathrm { m g / d L }$ to 848 mg/dL,.

20-day In-house Precision

The studies followed CLSI EP5-A2, where three or four levels of samples were each tested fourtimes a day for 20 days. The results were as follows:

# Precision Summary:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean (mg/dL)</td><td rowspan=1 colspan=1>Within-Run %CV</td><td rowspan=1 colspan=1>Total %CV</td></tr><tr><td rowspan=1 colspan=1>Total Cholesterol</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>..   116.5</td><td rowspan=1 colspan=1>….…0.9…</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>n= 80 per level</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>182.8</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>258.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>HDL</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>35.3</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>n= 80 per level</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>60.0</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>101.6</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>LDL</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>37.7</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>n- 80 per level</td><td rowspan=1 colspan=1>Level 2 .</td><td rowspan=1 colspan=1>104.3</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>3.5</td></tr><tr><td rowspan=1 colspan=1>· •      ,</td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>175.8</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>Level 4</td><td rowspan=1 colspan=1>299.3</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>-      2.7</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>TG</td><td rowspan=1 colspan=1>Level 1</td><td rowspan=1 colspan=1>32.8</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>n= 80 per level</td><td rowspan=1 colspan=1>Level 2</td><td rowspan=1 colspan=1>129.7</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 3</td><td rowspan=1 colspan=1>366.5</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Level 4</td><td rowspan=1 colspan=1>620.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>2.4</td></tr></table>

Page 7 of 14

EPY $\circledast$ Hitachi Chemical Dlagnostics, Inc. 630 Clyde Court, Mountain Vlew, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745

<table><tr><td>• i</td><td></td><td></td><td></td></tr></table>

Interference Testing

The studies followed CLSI EP7-A2. The data demonstrated that none of the four analytes were affected by high levels of the following substances at the levels noted:

Hemoglobin: no interference up to $1 0 0 0 ~ \mathrm { m g / d L }$ for CHO and LDL; $5 0 0 ~ \mathrm { m g / d L }$ for HDL and TG Unconjugated bilirubin no interference up to ${ \mathrm { 5 0 ~ m g / d L } }$ for CHO, HDL, and TG; $2 5 ~ \mathrm { m g / d L }$ for LDL Lipemia: no interference up to $2 0 0 0 ~ \mathrm { m g / d L }$ for CHO; up to $7 2 5 ~ \mathrm { m g / d L }$ for HDL and up to $6 1 4 { \mathrm { ~ m g / d L } }$ for LDL (TG: N/A) Ascorbic acid: no interference up to $5 0 ~ \mathrm { m g / d L }$ with any of the four test systems

Method Comparisons

The method comparison studies evaluated a minimum of 109 serum samples; matched aliquots were assayed with both the Hitachi Clinical Analyzer with S TEST reagent cartridges for CHO, HDL, LDL, and TG and the Roche/Hitachi cobas. The data were analyzed by least squares linear regression (Hitachi $=$ y-axis), and the results were as follows:

Cholesterol (mg/dL)   
$\mathtt { n } = 1 1 3$   
$\mathrm { y } = 0 . 9 8 \mathrm { x } + 2 . 2$   
correlation coefficient $( \mathbf { r } ) = 0 . 9 9 6$   
$9 5 \%$ confidence interval of the slope $= 0 . 9 6$ to 1.00   
$9 5 \%$ confidence interval of the y-intercept $= . 1 . 7$ to 6.1   
HDL (mg/dL)   
${ \mathfrak { n } } = 1 0 9$   
$\mathbf { y } = 0 . 9 9 \mathbf { x } + 5 . 4$ EY : !   
correlation coefficient ${ \bf ( r ) } = 0 . 9 8 6$   
$9 5 \%$ confidence interval of the slope $= 0 . 9 6$ to 1.03   
$9 5 \%$ confidence interval of the $\overset { 1 } { \mathbf { y } }$ intercept $\dot { = } 3 . 6$ to 7.3   
LDL (mg/dL)   
$\mathfrak { n } = \mathfrak { l } 2 2$   
$\mathrm { y } = 0 . 9 4 \mathrm { x } + 7 . 6$ EPY   
correlation coefficient $( \mathbf { r } ) = 0 . 9 \dot { 8 } 1$   
$9 5 \%$ confidence interval of the slope $= 0 . 9 0$ to 0.97   
$9 5 \%$ confidence interval of the y-intercept $= 3 . 0$ to 12.1 TG (mg/dL)   
$\mathfrak { n } = 1 1 1$   
$\mathrm { y } = 1 . 0 4 \mathrm { x } + 6 . 7$   
correlation coefficient $\mathbf { \Psi } ( \mathbf { r } ) \dot { } = 0 . 9 9 8$ . .   
$9 5 \%$ confidence interval of the slope $= 1 . 0 3$ to 1.05

Page 9 of 14

![](images/1e437ca55abb026d24cd981dd16044cddf1491f27eca79504f163da47f6dc94d.jpg)

Matrices Comparisons

A study was performed to validate the use of heparinized plasma as well as serum for the Hitachi Clinical Analyzer with S TEST reagent cartridges for CHO, HDL, LDL, and TG. Approximately 40 matched serum/plasma samples that spanned the four dynamic ranges were assayed in singleton and the results were compared using least squares liner regression (plasma $\asymp$ y-axis). The performance characteristics were as follows.

Cholesterol (mg/dL)   
$\mathbf { y } = 1 . 0 0 \mathbf { x } - 3 . 0$   
correlation coefficient ${ \bf ( r ) } = 0 . 9 9 9$   
$9 5 \%$ confidence interval of the slope $= 0 . 9 9$ to 1.01   
$9 5 \%$ confidence interval of the y-intercept $= - 5 . 5$ to -0.6   
HDL (mg/dL)   
$\mathrm { y } = 0 . 9 9 \mathrm { x } - 2 . 2$   
correlation coefficient $( \mathbf { r } ) = 0 . 9 9 9$   
$9 5 \%$ confidence interval of the slope $= 0 . 9 6$ to 1.00   
$9 5 \%$ confidence interval of the y-intercept $= - 3 . 9$ to -0.5   
LDL (mg/dL)   
$\mathrm { y } = 1 . 0 1 \mathrm { x } - 3 . 9$   
correlation coefficient ${ \bf \langle r \rangle } = 0 . 9 9 9$   
$9 5 \%$ confidence interval of the slope $= 0 . 9 9$ to 1.02   
$9 5 \%$ confidence interval of the y-intercept -6.4 to -2.3   
TG (mg/dL)   
$\mathrm { y } = 1 . 0 0 \mathrm { x } - 1 . 3$   
correlation coefficient ${ \bf \Pi } ( { \bf r } ) = 0 . 9 9 9$   
$9 5 \%$ confidence interval of the slope $= 0 . 9 8$ to 1.00   
$9 5 \%$ confidence interval of the y-intercept $= . 4 . 7$ to 2.1

# 807.92 (b)(2): Brief Description of Clinical Data

Studies for precision and method comparisons (accuracy) were performed at three external POLtype sites to evaluate the Hitachi Clinical Analyzer with S TEST reagent cartridges for CHO, HDL, LDL, and TG in one of its targeted intended use environments, the physician's office laboratory.

$\circledast$ Hitachi Chemical Diagnostics, Inc. 630 Clyde Court, Mountain Vlew, CA 94043-2239 Tel: 800 233 6278 Fax: 650 969 2745

For the external site precision study, each site received three blinded serum samples (the Precision Panel, labeled A; B, and C) that were chosen to represent low, intermediate, and high concentrations of each analyte. Each sample was assayed six times per day for five days, reporting 30 results per level per analyte. Precision estimates for within-run precision and total precision were as follows:

Total Cholesterol $\bf ( m g / d L )$ ${ \mathfrak { n } } = 3 { \mathbf { 0 } }$ replicates per sample per site   

<table><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-run Precision</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>121.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>123.5</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>123.5</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>182.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>185.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>185.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.7%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>242.3</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>245.8</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>247.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>1.4%</td></tr></table>

.1.

HDL Cholesterol $\bf ( m g / d L )$ $\mathbf { n } = 3 \mathbf { 0 }$ replicates per sample per site   

<table><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-run Precision</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>37.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>36.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>35.8</td><td rowspan=1 colspan=1>0.7  :</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.7%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&#x27;:</td><td rowspan=1 colspan=1>ri..</td><td rowspan=1 colspan=1>… -ii</td><td rowspan=1 colspan=1>1n:131</td><td rowspan=1 colspan=1>·&#x27;</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>67.1</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>68.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>64.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>105.9</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>106.3</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>102.7</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.6%</td></tr></table>

LDL Cholesterol (mg/dL) $\ddot { \mathbf { n } } = 3 \mathbf { 0 }$ replicates per sample per site   

<table><tr><td>Site</td><td>Sample</td><td></td><td>Mean</td><td>Within-run Precision</td><td></td><td>Total Precision</td><td></td></tr><tr><td></td><td>•</td><td></td><td></td><td>SD (mg/dL)</td><td>%CV</td><td>SD (mg/dL)</td><td>%CV</td></tr></table>

Page 11 of 14

$\circledast$ Hitachl Chemical Dlagnostics, Inc. .i ..: 630Clyde Court, Mountain Vlew, CA04043-2239Tel: 800 233 6278 F 650 969 2745

![](images/dbe62246dac4e93e9ca9c06153dc7e7e3f20c3e2c5d06232feb37d52982957eb.jpg)

<table><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>41.0</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>42.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>41.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>108.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>112.3</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>1.5%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>109.1</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>183.5</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.7%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>191.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>181.2</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.7%</td></tr></table>

Triglycerides $\bf ( m g / d L )$ cYanmalo $\mathbf { n } = 3 \mathbf { 0 }$ replicates per sample per site   

<table><tr><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-run Precision</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>. **..</td><td rowspan=1 colspan=1>; </td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD (mg/dL)</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>32.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>33.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>31.4</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.1%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>115.0</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>120.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>115.4</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>291.0</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>301.5</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>C</td><td rowspan=1 colspan=1>289.1</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.1%</td></tr></table>

For the external site method comparisons study, each POL site received approximately 50 blinded serum samples that were chosen to represent as ful a range of analyte concentrations as possible, and a central laboratory received a matched aliquot for each serum sample. Each sample was assayed by the Hitachi system at the POL sites, and by the Roche cobas 6000 (predicate system) at the central laboratory. The results were analyzed by least squares linear regression (Hitach $\begin{array} { r } { \dot { \mathbf { l } } = \mathbf { y } - \pmb { \updownarrow } } \end{array}$ xis), and the performance characteristics were as follows:

….   
POL ACCURACY DATA SUMMARY- Total Cholesterol mg/dI   

<table><tr><td rowspan=1 colspan=1>Site #</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>&quot;p&quot;·</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>CI*,Slope</td><td rowspan=1 colspan=1>CI Intercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>60 to 329</td><td rowspan=1 colspan=1>y=0.97x+2.5</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>3.45</td><td rowspan=1 colspan=1>0.95 to 0.98</td><td rowspan=1 colspan=1>-1.1 to 6.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>60 to 334</td><td rowspan=1 colspan=1>y= 0.98x +4.1</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>4.92</td><td rowspan=1 colspan=1>0.95 to 1.00</td><td rowspan=1 colspan=1>-1.0 to 9.3</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>60 to 333</td><td rowspan=1 colspan=1>y= 1.00x +0.7</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>13.54</td><td rowspan=1 colspan=1>0.94 to 1.08</td><td rowspan=1 colspan=1>-13.7 to 15.2</td></tr></table>

$4 9 5 \%$ Confidence Interval

POL ACCURACY DATA SUMMARY- HDL mg/dL   

<table><tr><td rowspan=1 colspan=1>Site #</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>&quot;p&quot;</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>CISlope</td><td rowspan=1 colspan=1>CI Intercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>15 to 111</td><td rowspan=1 colspan=1>y^=0.96x+7.6</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>4.22</td><td rowspan=1 colspan=1>0.91 to 1.00</td><td rowspan=1 colspan=1>4.9 to 10.3</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>16 to 114</td><td rowspan=1 colspan=1>y=0.97x +7.9</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>3.90</td><td rowspan=1 colspan=1>0.91 to 1.03</td><td rowspan=1 colspan=1>4.8 to 11.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>14 to 115</td><td rowspan=1 colspan=1>y=0.93x +7.8</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>3.67</td><td rowspan=1 colspan=1>0.89 to 0.98</td><td rowspan=1 colspan=1>5.3 to 10.3</td></tr></table>

POL ACCURACY DATA SUMMARY- LDL mg/dL   
Page 13 of 14   

<table><tr><td rowspan=1 colspan=1>Site #</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>“6p&quot;</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>CI·Slope</td><td rowspan=1 colspan=1>CI Intercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>26 to 274</td><td rowspan=1 colspan=1>y=0.94x+3.8</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>.8.08</td><td rowspan=1 colspan=1>:.0.90 to 0.99</td><td rowspan=1 colspan=1>-1.7 to 9.4</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>26 to 283</td><td rowspan=1 colspan=1>y=0.95x +3.6</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>9.42</td><td rowspan=1 colspan=1>0.89 to 1.01</td><td rowspan=1 colspan=1>-3.5 to 10.8</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>25 to 276</td><td rowspan=1 colspan=1>y= 0.93x +6.4</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>8.04</td><td rowspan=1 colspan=1>0.89 to 0.98</td><td rowspan=1 colspan=1>0.6 to 12.3</td></tr></table>

$\circledast$ HltachI Chemical Dlagnostics, Inc. 630 Clyde Court, Mountain Vlew, CA 94043-2239Tel: 800 233 6278 Fax: 650 969 2745

<table><tr><td>www.hcdiagnostics.com</td></tr></table>

POL ACCURACY DATA SUMMARY- TG mg/dL   

<table><tr><td rowspan=1 colspan=1>Site #</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>&quot;r&quot;</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>CISlope</td><td rowspan=1 colspan=1>CI Intercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>36 to 619</td><td rowspan=1 colspan=1>y=1.05x+4.9</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>6.95</td><td rowspan=1 colspan=1>1.04 to 1.07</td><td rowspan=1 colspan=1>1.4 to 8.4</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>21 to 712</td><td rowspan=1 colspan=1>y=0.94x+3.3</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>8.06</td><td rowspan=1 colspan=1>0.93 to 0.96</td><td rowspan=1 colspan=1>0.1 to 6.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>35 to 605</td><td rowspan=1 colspan=1>y=1.07x-6.5</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>7.78</td><td rowspan=1 colspan=1>1.05 to 1.10</td><td rowspan=1 colspan=1>-10.1 to -2.9</td></tr></table>

# 807.92 (b)(3): Conclusions from Nonclinical and Clinical Testing

Nonclinical and clinical testing was performed for the Hitachi Clinical Analyzer with reagent cartridges for CHO, HDL, LDL, and TG. The test system was shown to be safe and effective for its intended use.

;

Hitachi Chemical Diagnostics, Inc.   
c/o Erika B Ammirati, RAC, MT (ASCP) Consultant   
575 Shirlynn Court,   
Los Altos, CA 94022

Re: k1 11753 Trade/Device Name: Hitachi Clinical Analyzer S TEST Reagent Cartridges- Cholesterol (CHO), HDL Cholesterol (HDL), LDL Cholesterol (LDL), And Triglycerides (TG) Regulation Number: 21 CFR 862.1705 Regulation Name: Triglyceride test system. Regulatory Class: I, meets limitations of exemption 862.9 (c) (4) Product Code: CDT, CHH, LBS, MRR, JE Dated: December 9, 2011 Received: December 12, 2011

Dear Ms. Ammirati:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition. FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21

Page 2-

If you desire specific advice for your device on our labeling regulation (21 CFR Par 801), please contact the Office of In Viro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the reat nti "Misandi  ce   otati"  C Pa 80.9.F (') Division of Postmarket Surveillance a (301) 796-5760. For questions regarding the reporting of avere evets under the MDRegulation (21 CFR Par 803), please to   
htt:/ww.a.ov/MedicaDevices/Safety/ReporaProblem/ault.htor the CDRH'sOff Surveillance and Biometrics/Division of Postmarket Surveillance.

Yumy t hltin nyurl ndehec o he Di  all Manufacturers, International an Consumer Assistance at its tolree number (800) 638-2041or 3019- 5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/8894febcf1d432e2621e05a09d98272c217d9eb356b5e0d2824d0b9cdaac8e14.jpg)

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# INDICATIONS FOR USE

# 510(k) Number (if Known):

K111753

# Device Name:

Hitachi Clinical Analyzer S TEST Reagent Cartridges- Cholesterol (CHO), HDL cholesterol (HDL), LDL cholesterol (LDL), and triglycerides (TG)

# Indications for Use:

The Hitachi Clinical Analyzer with S TEST reagent cartridges for total cholesterol (CHO), HDL cholesterol (HDL), LDL cholesterol (LDL), and triglycerides (TG) is intended for the quantitative measurements of CHO, HDL, LDL, and TG in serum or heparinized plasma. The test system is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

• Cholesterol measurements are used in the diagnosis and treatment of disorders involving exes cholesterol in the blood, and lipid and lipoproteinmetabolismdisorders.

HDL measurements (lipoproteins) are used in the diagnosis and treatment of lipid disorder: (such as diabetes mellitus), atheroscerosis, and various liver and renal diseases.

• LDL measurements (lipoproteins) are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases.

Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, or various endocrine disorders.

Over-The-Counter Use (21 CFR 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)